Login / Signup

Directed evolution of the B. subtilis nitroreductase YfkO improves activation of the PET-capable probe SN33623 and CB1954 prodrug.

Michelle H RichAbigail V SharrockAmir AshoorzadehAdam V PattersonJeff B SmaillDavid F Ackerley
Published in: Biotechnology letters (2020)
The enhanced activation of the PET imaging probe SN33623 and CB1954 prodrug exhibited by the lead evolved variant of YfkO offers prospects for improved enzyme-prodrug therapy.
Keyphrases
  • pet imaging
  • cancer therapy
  • drug release
  • positron emission tomography
  • living cells
  • quantum dots
  • drug delivery
  • computed tomography
  • pet ct
  • stem cells
  • bone marrow